About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Solasia Pharma K.K.(4597) Summary

4597
TSE Growth
Solasia Pharma K.K.
31
JPY
-2
(-6.06%)
Apr 4, 3:30 pm JST
0.21
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
30.5
Apr 4, 11:24 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.85
Yield
ー%
Margin Trading Ratio
2.75
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
32 JPY 0.21 USD
Previous Close Apr 3
33 JPY 0.22 USD
High Apr 4, 9:01 am
34 JPY 0.23 USD
Low Apr 4, 12:37 pm
30 JPY 0.20 USD
Volume
10,433,200
Trading Value
0.33B JPY 2.26M USD
VWAP
31.57 JPY 0.22 USD
Minimum Trading Value
3,100 JPY 21 USD
Market Cap
6.77B JPY 0.05B USD
Number of Trades
867
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
Slightly High
1-Year Average
740
1-Year High Jul 25, 2024
6,835
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 5,876,700 21,993,800 3.74
Mar 21, 2025 6,530,200 23,343,800 3.57
Mar 14, 2025 6,983,400 22,634,200 3.24
Mar 7, 2025 5,769,400 23,166,800 4.02
Feb 28, 2025 5,736,500 23,994,500 4.18
Company Profile
Solasia Pharma K.K. is a biopharmaceutical venture company focused on cancer and malignant tumor drug discovery. The company engages in the development of pharmaceuticals and medical devices, with a primary focus on clinical development.
Sector
Pharmaceuticals
Solasia Pharma K.K. operates as a biopharmaceutical venture company specializing in the oncology field, developing both pharmaceuticals and medical devices. The company primarily concentrates on clinical development, introducing promising new drug candidates and conducting trials in Japan and other Asian countries. With multiple development pipelines, Solasia focuses on treatments for malignant tumors and supportive care medications. Their product portfolio includes darinaparsin for peripheral T-cell lymphoma, a transdermal granisetron preparation for preventing chemotherapy-induced nausea and vomiting, and a medical device aimed at alleviating pain from oral mucositis. The company's business model encompasses the entire process from clinical development to regulatory submission and out-licensing of marketing rights. Solasia aims to generate revenue through out-licensing to pharmaceutical companies, which includes sales revenue, milestone payments, and royalty income.